TAIM
BMRN icon

TD Ameritrade Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

TD Ameritrade Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22
Closed -$2K – 550
2023
Q1 		$2K Hold
22
– – ﹤0.01% 468
2022
Q4 		$2K Sell
22
-54
-71% -$5.07K ﹤0.01% 479
2022
Q3 		$6K Sell
76
-57
-43% -$5.08K ﹤0.01% 410
2022
Q2 		$11K Sell
133
-18
-12% -$1.43K ﹤0.01% 425
2022
Q1 		$12K Buy
151
+12
+9% +$1K ﹤0.01% 472
2021
Q4 		$12K Buy
139
+95
+216% +$7.84K ﹤0.01% 465
2021
Q3 		$3K Sell
44
-36
-45% -$2.84K ﹤0.01% 546
2021
Q2 		$7K Buy
80
+42
+111% +$3.33K ﹤0.01% 495
2021
Q1 		$3K Hold
38
– – ﹤0.01% 554
2020
Q4 		$3K Sell
38
-6
-14% -$476 ﹤0.01% 554
2020
Q3 		$3K Hold
44
– – ﹤0.01% 546
2020
Q2 		$5K Sell
44
-5
-10% -$497 ﹤0.01% 506
2020
Q1 		$4K Sell
49
-14
-22% -$1.21K ﹤0.01% 494
2019
Q4 		$5K Buy
63
+58
+1,160% +$4.38K ﹤0.01% 512
2019
Q3 		$0 Buy
+5
New +$385 ﹤0.01% 634
2019
Q1 		– Sell
-23
Closed -$2K – 573
2018
Q4 		$2K Buy
23
+11
+92% +$1.05K ﹤0.01% 526
2018
Q3 		$1K Buy
12
+2
+20% +$200 ﹤0.01% 525
2018
Q2 		$1K Buy
+10
New +$876 ﹤0.01% 407

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TD Ameritrade Investment Management's BMRN Position: Q2 2023 in Review

TD Ameritrade Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 22 shares — an estimated $2K sold.

TD Ameritrade Investment Management first reported a position in BMRN in Q2 2018 and held it in 18 quarters. The position peaked at $12K in Q1 2022. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • TD Ameritrade Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 22 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $2K.
  • TD Ameritrade Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 18 quarters.
  • TD Ameritrade Investment Management's BioMarin Pharmaceuticals position peaked at $12K in Q1 2022.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on TD Ameritrade Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.